Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna Inc. shares dove more than 5% in after-hours trading Thursday, after the company announced that a study into a flu vaccine candidate failed to reach one of its goals.

Moderna stock falls 5% after flu vaccine study results

mRNA-1010 demonstrated superiority on seroconversion rates for A/H3N2 and A/H1N1, superiority on geometric mean titer ratios for A/H3N2, and non-inferiority on geometric mean titer ratios for A/H1N1 Non-inferiority was not met for seroconversion rates and geometric mean titer ratios for the influenza B/Victoria- and B/Yamagata-lineage strains mRNA-1010 showed an acceptable safety and tolerability profile Separate parallel pivotal Phase 3 efficacy study has now accrued over 200 PCR-confirmed cases, almost all influenza A consistent with the burden of disease in older adults; an independent DSMB is expected to review the first interim analysis of efficacy by the end of 1Q mRNA-1010 is one of five influenza vaccine candidates being evaluated by Moderna CAMBRIDGE, MA / ACCESSWIRE / February 16, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced interim results from its pivotal Phase 3 safety and immunogenicity trial of mRNA-1010 (P301), an mRNA-based seasonal influenza (flu) vaccine candidate, in adults. The Phase 3 randomized trial was designed to evaluate the safety and immunogenicity of mRNA-1010 in adults 18 years and older in the Southern Hemisphere.

Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, a Seasonal Influenza Vaccine Candidate

Cirrus Logic

On a hilltop in your town live two people. Joseph has an income of $400,000 a year but little savings.

Moderna and Cirrus Logic Are Balance Sheet Powerhouses

American Tower

Booking Hlds

EOG Resources

Home Depot

Intuit

NVIDIA

Pioneer Natural Resources

Walmart

Companies with a strong earnings growth rate are usually on traders' radars. Thus, it is important to keep track of stocks that are due to announce their earnings report card.

The 10 Biggest Companies Reporting Earnings in the Fourth Week of February 2023

Moderna Inc. MRNA, +0.95% said Tuesday it will keep its COVID-19 vaccines available and free for all people in the U.S. after the public-health emergency ends. For uninsured or underinsured people, Moderna said it will provide the vaccine at no cost through its patient assistance program.

Moderna promises to keep COVID vaccine free

Sen. Bernie Sanders, chairman of the Senate health committee, confirmed in a statement that Moderna CEO Stéphane Bancel will testify on the company's plans to increase the price of its Covid vaccine.

Moderna CEO Stephane Bancel will testify before Senate next month on Covid vaccine price hike

Is Moderna stock a buy after unveiling promising results for its Pfizer- and GSK-rivaling RSV vaccine? Is MRNA stock a buy now?

Is Moderna Stock A Buy As It Faces Off With Pfizer, GSK In The Massive RSV Market?

Abbott Labs

Lululemon Athletica

Candy? Flowers? These Top Stocks Offer You Something Even Sweeter

Moderna Inc (NASDAQ:MRNA) stock was last seen trading at $169.88.

Signal Says Buy the Dip on This Vaccine Stock

Align Technology

Bath and Body Works

Enphase Energy

First Solar

Hearts, flowers and CPI data. Get ready for Tuesday.

Here are five companies to pick if Goldman Sachs is right about the stock market being flat in 2023

DaVita

VanEck Vectors Pharmaceutical ETF

Active investors can navigate the boom or bust biotech sector with the help of strategies like C-suite buying, cash to value and cash flow. Passive investors seeking a defensive position might just purchase the VanEck Pharmaceutical ETF and call it a year.

Betting On Biotech

WisdomTree U.S. Earnings 500 Fund

Renaissance IPO ETF

Pfizer

Pfizer and Moderna profited by developing vaccines at a breakneck pace, but should investors add them to their portfolios in 2023? As the race to develop COVID-19 vaccines became paramount, Moderna's years of mRNA research would finally pay off.

Pandemic Profits In Healthcare

Amgen

Exact Sciences

Gilead Sciences

GlaxoSmithKline

Immunocore Holdings

Eli Lilly

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

The industry is home to some large-cap heavyweights, including Amgen Inc. (NASDAQ: AMGN), Gilead Sciences Inc. (NASDAQ: GILD), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), and Moderna Inc. (NASDAQ: MRNA), among others.

Is Biotech Immunocore About To Make A 25% Price Move?

CRISPR Therapeutics

Inmode Ltd

These stocks all fell by double digits last year.

3 No-Brainer Growth Stocks to Buy in 2023

Personalis Inc

FREMONT, Calif.--( BUSINESS WIRE )--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the companies have signed a new agreement to continue using the Personalis NeXT Platform® as part of upcoming clinical studies evaluating mRNA-4157/V940, an investigational personalized cancer vaccine, jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada. The platform, which was also utilized in the vaccine candidate's Phase 2b clinical study, will be used to sequence genomic information from a patient's tumor sample to identify the unique genetic mutations that are most likely to generate a tailored antitumor response.

Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials

AbCellera Biologics

BioNTech SE

Chimerix

iTeos Therapeutics, Inc.

Vir Biotechnology

You don't have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edge of medical science.

The 7 Most Undervalued Biotech Stocks to Buy in February 2023

CAMBRIDGE, MA / ACCESSWIRE / February 2, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 23, 2023 to report its fourth quarter and full year 2022 financial results, and provide a corporate update.

Moderna to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 23, 2023

Biogen

Charter Communications

Cognizant Technology Solutions

Intel

Micron Technology

Thanks to the wild events of 2022, discerning investors enjoy plenty of bargains, particularly in the arena of the most undervalued Nasdaq stocks. Given the exchange's bias toward technology players (including biotech), wagering in this space carries the advantage of relevance.

The 7 Most Undervalued Nasdaq Stocks to Buy in February 2023

Moderna stock has dropped 60% from its peak.

This Discount Growth Stock Is a Once-in-a-Decade Buying Opportunity Right Now

Moderna Inc.'s MRNA shares were down 2.8% in trading on Tuesday. Pfizer Inc. PFE, which makes a competing COVID-19 vaccine to Moderna's Spikevax, on Tuesday put out guidance for 2023, saying it expects a total of $13.5 billion in sales of its COVID shot for the year.

Moderna's stock is down as Pfizer lowers revenue estimates for its COVID vaccine for 2023

Moderna (MRNA) announces that the FDA granted Breakthrough Therapy Designation to its respiratory syncytial virus (RSV) vaccine candidate, mRNA-1345 for the prevention of respiratory disease in older adults.

Moderna (MRNA) RSV Jab For Older Adults Gets FDA Breakthrough Tag

The Food and Drug Administration granted Moderna's experimental RSV vaccine an expedited review, but Moderna stock dipped Monday.

The RSV Vaccine Battle Wages On With Moderna Scoring A Win Vs. Pfizer, GSK

Moderna Inc. MRNA, -2.01% said Monday that the Food and Drug Administration granted the company's experimental respiratory syncytial virus vaccine a Breakthrough Therapy Designation. Moderna said it plans to apply for approval in the first half of this year.

Moderna's RSV vaccine gets Breakthrough Therapy status

Designation based on positive topline data from the ConquerRSV Phase 3 pivotal efficacy trial, which demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults CAMBRIDGE, MA / ACCESSWIRE / January 30, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced mRNA-1345, an investigational mRNA vaccine candidate for respiratory syncytial virus (RSV), has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the prevention of RSV-associated lower respiratory tract disease (RSV-LRTD) in adults aged 60 years or older. The designation was based on positive topline data from the ConquerRSV Phase 3 pivotal efficacy trial.

Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, An Investigational Respiratory Syncytial Virus (RSV) Vaccine Candidate

Teladoc

Two of these stocks have what it takes to rebound and deliver lasting gains.

2 Struggling Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague

News for Moderna Stock (MRNA)